ARVN (Arvinas) Short Interest


ARVN Arvinas Inc ARVN
70 GF Score
Price $8.03
GF Value $11.80
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Arvinas Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ARVN vs EIKN, GYRE, TECX: Short Interest Comparison

For the Biotechnology subindustry, Arvinas's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arvinas Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arvinas's Short Interest distribution charts can be found below:

* The bar in red indicates where Arvinas's Short Interest falls into.


ARVN
70GF Score
Arvinas Inc ARVN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arvinas (ARVN) Overvalued in 2026?

Based on GuruFocus' analysis, Arvinas stock appears to be undervalued. The current stock price of $8.03 is trading 31.9% below its estimated GF Value™ of $11.80. GuruFocus considers Arvinas to be Possible Value Trap.

Key valuation signals for ARVN:

  • Short Interest:
  • GF Value™: $11.80 vs. price of $8.03 (31.9% below fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the ARVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arvinas Business Description

Address 395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
70GF Score

Get the complete analysis for ARVN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.03
Price
$11.80
GF Value